Our lives won’t return to normal without a COVID-19 vaccine. Fred Hutch experts have been at the forefront of an unprecedented, global effort to conceive of and test safe and effective vaccines against this virus, build factories to manufacture them and provide the logistics to deliver them to the arms of billions of people.
It’s about saving lives, protecting our way of life and making history. Here’s how it is will happen.
COVID-19 vaccines are remarkably effective, but their protection can wane over time. That can lead to breakthrough infections in vaccinated people. A booster — an extra dose, taken several months after your last shot — can fortify your immune response to the vaccine.
Currently, everyone over 18 is eligible for a booster. Evidence suggests boosters will be a good way to maintain peak protection, particularly for those who are older, have chronic health conditions, or are at higher risk due to their occupation or where they live.
Read about what vaccine boosters are, how they work, and why they’re being recommended.
Fred Hutch is working with the National Institutes of Health and others to design and run human clinical trials for five to seven of the most promising vaccine candidates developed by industry partners capable of making millions of doses. These candidates must pass three phases of human testing. Vaccine trials can take five years to design and complete. The goal: to get one or more COVID-19 vaccines ready to go by the end of 2020. In December, two vaccines received emergency use authorization.
Making enough vaccine to protect the world from COVID-19 will require an astonishing scale-up of global manufacturing. U.S. experts say 4.4 billion doses are needed to cover adults worldwide, a figure that would jump if shots are needed for kids. No one pharmaceutical company can meet that demand. Hence, current strategy supports development of many different vaccine types and building factories in advance, in hopes of approval. The U.S. has already bought vaccines “at risk” so that those doses — now in production — could be ready immediately upon approval. Bill Gates pledged to help fund factories for seven different vaccine candidates, knowing not all will succeed. Yet factories alone won’t work unless their supply lines for biological ingredients, immune-boosting adjuvants, and even the specialized glass vials and rubber stoppers to hold vaccines are stocked. The Trump administration initiative to have 300 million doses ready by January 2021 was called “Operation Warp Speed.”
– Bill Gates, Chairman, Bill & Melinda Gates Foundation